Mergers & Acquisitions ·
Edgewise Therapeutics reported second quarter 2026 financial results and announced the completion of a transaction to…
EWTXEdgewise Therapeutics, Inc.
Edgewise Therapeutics reported second quarter 2026 financial results and announced the completion of a transaction to sell its sevasemten and muscular dystrophy business to Servier for $1.55 billion in upfront cash, with up to $1.1 billion in potential milestones totaling $2.65 billion. The company also disclosed positive top-line data from the 12-week Phase 2 CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy and plans to initiate a Phase 3 trial in Q4 2026. R&D expenses were $47.5 million, G&A was $14.4 million, resulting in a net loss of $57.3 million or $0.53 per share. Cash and marketable securities stood at $460.7 million as of June 30, 2026, excluding the July upfront proceeds which would bring the pro forma balance to approximately $2.01 billion. Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel muscle-targeted therapeutics for cardiovascular diseases.